A One-Year, Prospective, Randomized, Controlled Study Evaluating The Efficacy Of Switching From The Twice Daily Tacrolimus Formulation To The Extended Release, Once Daily Formulation To Reduce The Framingham Cardiovascular Risk Scores.

Trial Profile

A One-Year, Prospective, Randomized, Controlled Study Evaluating The Efficacy Of Switching From The Twice Daily Tacrolimus Formulation To The Extended Release, Once Daily Formulation To Reduce The Framingham Cardiovascular Risk Scores.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 11 Jan 2017

At a glance

  • Drugs Tacrolimus (Primary)
  • Indications Renal transplant rejection
  • Focus Biomarker; Pharmacodynamics
  • Acronyms ESTTEROD
  • Most Recent Events

    • 05 Jan 2017 Planned End Date changed from 1 Jun 2016 to 1 Jul 2017.
    • 05 Jan 2017 Planned primary completion date changed from 1 Jun 2016 to 1 Jul 2017.
    • 02 Jun 2015 Planned End Date changed from 1 Apr 2014 to 1 Jun 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top